New OB-GYN Guidance Endorses Hormone Therapy for Menopause Symptoms

POLICY WIRE — Washington, United States — The American College of Obstetricians and Gynecologists has issued updated clinical guidance regarding the management of common perimenopause and menopause symptoms, designating hormone replacement therapy as a primary recommendation for patients experiencing hot flashes and night sweats.

This marks the first time in more than ten years that the premier professional organization for U.S. obstetricians and gynecologists has updated its official recommendations concerning hormone treatments for menopause and perimenopause.

Dr. Kameelah Phillips, an OB-GYN and menopause specialist, stated that hormone replacement therapy is now considered the first line of defense for vasomotor symptoms such as hot flashes, night sweats, and sleep disturbances.

Phillips noted in an interview on CBS Mornings that previous approaches relied on alternative suggestions like antidepressants, exercise, or a glass of wine, which often proved unhelpful. She emphasized that hormones are now being utilized in mainstream care.

Most menopausal symptoms stem from sharp declines in estrogen and progesterone, which typically occur when women reach their late 40s or early 50s. These hormonal reductions trigger hot flashes, night sweats, and can simultaneously cause decreased bone density, thereby elevating the risk of fractures or osteoporosis.

Phillips explained that hormone replacement therapy can help eliminate these symptoms entirely.

Delivery mechanisms for hormone replacement therapy vary and include options such as pills, sprays, patches, gels, or vaginal rings designed to release dosages directly into the bloodstream. Additionally, some patients find relief through low-dose vaginal estrogen therapy.

In an official statement addressing the new guidelines, ACOG emphasized that while menopause is a normal and natural stage of life, women do not have to suffer through the associated symptoms without assistance.

However, the organization noted that hormone replacement therapies are not suitable for every individual. Patients with prior medical histories involving blood clots, liver disease, and stroke should avoid utilizing them. ACOG also advises individuals with a personal history of breast cancer to steer clear of these treatments.

Recent research indicates that proper dosing and patient age considerations can render the treatment safe for numerous patients. Furthermore, a 2024 study encompassing over 10,000 women suggests that it may also assist in slowing biological aging.

The ACOG recommendations advise that women should initiate hormone replacement therapy prior to turning 60 years old or within a 10-year window of onset for menopause.

For individuals who qualify, alternative pathways remain available. Phillips advised patients to schedule consultations with a menopause-trained specialist.

Phillips stressed that there are genuinely effective non-hormonal options accessible for these women, underscoring why these decisions require detailed discussions with a healthcare provider.

Reporting by Policy-Wire (PW)